Compare Gerdau S.A. Common Stock (GGB) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gerdau S.A. Common Stock vs Smith & Nephew plc — how do they compare? Gerdau S.A. Common Stock trades at $5.12 (market cap $9.16B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Gerdau S.A. Common Stock pays the higher dividend (3.67%). Which is the better fit depends on your goals — on Pluang, investors hold Gerdau S.A. Common Stock for 1 Days and Smith & Nephew plc for 121 Days on average.
| GGB | SNN | |
|---|---|---|
Market Cap | $9.16B | $11.10B |
Volume | 16,238,936 | 1,051,703 |
Sector | Basic Materials | Health |
52-Week High | $5.17 | $37.17 |
52-Week Low | $3.15 | $26.42 |
Typical Hold Time | 1 Days | 121 Days |
Enterprise Value | $11.10B | $14.13B |
Dividend Yield | 3.67% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gerdau S.A. Common Stock
Gerdau is a steel producer with operations across the Americas. It makes long steel, specialty steel, and other products for construction and industrial markets.
Read more on GGB →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
